BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Money on the Move: July 14 – 21

  More money means more progress for potentially life-saving therapies. Here’s a peek at some biopharma companies adding to their books this week.

  July 21, 2021

   · 

  5 min read

   · 

  Kate Goodwin
• 

  Business

  Biogen Ties Up with Mirimus for Neurological Indications, and Other Collaborations

  Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.

  July 21, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Genentech’s Combo Therapy for Rare Blood Cancers Scores Breakthrough Designation

  Genentech announced that the FDA has green-lit the Venclexta classification and azicitidine combination as a Breakthrough Therapy Drug.

  July 21, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  FDA Gives OK for Viracta’s Phase Ib/II Trial of Oral Combo in Epstein-Barr Virus Tumors

  The study will also investigate the oral combination with PD-1 inhibitor pembrolizumab in EBV+ metastatic nasopharyngeal carcinoma (RM-NPC).

  July 21, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Industry Taking Notice of Araris Biotech’s Linker Technology for ADC Delivery

  The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.

  July 21, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Global Roundup: England’s Calyx Establishes US Toehold in North Carolina

  Biopharma companies from around the globe provide updates on their businesses and pipelines.

  July 21, 2021

   · 

  6 min read

   · 

  Alex Keown
• 

  Pharm Country

  J&J Highlight Massive Q2 Earnings While Covid Vaccine Doubts Grow and Legal Battles Rage

  As Johnson & Johnson touted $23.3 billion sales on its Q2 earnings call this morning, other news in the media hasn’t been as kind to the massive, global conglomerate.

  July 21, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  FDA

  Magenta Down After FDA Places Clinical Hold on IND for AML/MDS Drug

  The FDA placed a clinical hold on Magenta’s clinical program for acute myeloid leukemia and myelodysplastic syndrome, which made its shares drop nearly 7% this morning.

  July 21, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Study: Transplant From Mother’s Gut May Reverse Newborns’ Risk for Type 1 Diabetes

  Researchers say transplanting fecal microbiota from the mother into the newborn can reverse the risk for Type 1 diabetes for babies who had been exposed to antibiotic treatments early.

  July 21, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Policy

  Biogen’s Aduhelm: Slow to Launch with Controversy Continuing

  Biogen’s Aduhelm was approved on June 7, 2021, for Alzheimer’s patients, and the controversy continues to grow.

  July 21, 2021

   · 

  6 min read

   · 

  Mark Terry